This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Educational Activity

Novel Pharmacologic Targets for the Treatment of Negative Symptoms in Schizophrenia

Robert W. Buchanan, MD

Published: May 15, 2013

This CME activity is expired. For more CME activities, visit
Find more articles on this and other psychiatry and CNS topics:
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders


While positive symptoms of schizophrenia tend to respond well to antipsychotic therapy, negative symptoms remain refractory in many patients. Evidence for N-methyl-d-aspartate (NMDA) glutamate receptor hypofunction in patients with schizophrenia has led to establishing novel treatment targets for resolving those symptoms. This activity reviews glutamatergic agents in the treatment of negative and cognitive symptoms, including the NMDA receptor agonists and partial agonists glycine, d-serine, and d-cycloserine; the glycine transporter inhibitors sarcosine and RG1678; and ampakines, positive allosteric modulators of AMPA glutamate receptors.

Related Articles

Volume: 74

Quick Links: